tiprankstipranks
TipRanksStock Market NewsPFE NewsPfizer (PFE) Receives a Hold from Goldman Sachs
Blurbs

Pfizer (PFE) Receives a Hold from Goldman Sachs

Goldman Sachs analyst Chris Shibutani maintained a Hold rating on Pfizer (PFEResearch Report) today and set a price target of $51.00. The company’s shares closed last Tuesday at $52.04.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.3% and a 48.8% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Arcutis Biotherapeutics, and Nektar Therapeutics.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $57.08, implying an 8.3% upside from current levels. In a report issued on July 8, Morgan Stanley also maintained a Hold rating on the stock with a $49.00 price target.

See the top stocks recommended by analysts >>

Pfizer’s market cap is currently $296.8B and has a P/E ratio of 11.94.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Read More on PFE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More